派林生物(000403.SZ)：人凝血因子IX获得药品注册上市许可受理通知书

Core Viewpoint - Palin Bio (000403.SZ) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The human coagulation factor IX is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug significantly enhances the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding [1] - Hemophilia B is classified as a rare disease, and there is a long-term shortage of clinical medications, with existing treatments having room for improvement in active recovery rates [1] Group 2 - The company is committed to patient-centered approaches and aims to develop blood-derived drugs with high recovery rates [1]